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Available online 19 February 2015AbstractAluminum-containing adjuvants (alum) continue to be the most widely used adjuvants. It is common knowledge that these adjuvants pre-
dominantly induce humoral immunity, but some reports also describe their role combined with IL-12 in the induction of a Th1 immune response.
In this study we want to investigate if alum could be an adjuvant to be used as a component of a therapeutic vaccine that require the generation of
cell-mediated immunity. To demonstrate this concept we selected the human papillomavirus (HPV) 16-transformed mouse TC-1 cells as model
and the fusion protein LALF32-51-E7 as antigen. Our results suggest that LALF32-51-E7 combined with aluminum hydroxide adjuvant promotes a
Th1 immune response and consequently an anti-tumor response in the TC-1 tumor model. These results could have important application in
future clinical trials in women with low grade squamous intraepithelial neoplasia.
Copyright © 2015, Shanghai Hengrun Biomedical Technology Research Institute. Publishing Services By Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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For over 60 years, aluminum salts (alum) were the only
adjuvants approved for practical vaccination by the Food and
Drug Administration [1] and have been extensively used in the
prophylactic vaccination. Many researchers described that
alum is a very effective adjuvant for promoting humoral im-
munity and Th2 type T-cell responses, but it is not an effective
adjuvant for inducing Th1 immune responses [2,3]. The* Corresponding author. Tel.: þ53 7 271 6022.
E-mail address: milaid.granadillo@cigb.edu.cu (M. Granadillo).
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http://dx.doi.org/10.1016/j.jocit.2015.01.001
2352-1775/Copyright © 2015, Shanghai Hengrun Biomedical Technology Researc
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4reasons behind the poor effectiveness of alum in promoting
Th1 responses are not fully understood but may include the
promotion of IL-4 secreting granulocytes [3] and the inhibition
of IL-12 production by dendritic cells [4]. Other studies have
shown that alum combined with IL-12 can facilitate the in-
duction of Th1 immune response [5,6]. Despite the realized
efforts, it is surprising that yet is no consensus regarding the
mechanisms by which alum potentiate the immune system.
Whilst prophylactic vaccination aims to the induction of
antibody response, the therapeutic vaccination needs the
generation of a potent cell-mediated immune response. In this
study we want to investigate if aluminum hydroxide [Al(OH)3]
adjuvant could promote a cell-mediated immune response
when is combined with an antigen. To prove this concept weh Institute. Publishing Services By Elsevier B.V. This is an open access article
.0/).
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tumor model in mice, particularly the TC-1 model, because
these tumor cells strongly express MHC class I and constitutes
a suitable model to evaluate therapies that require the gener-
ation of cell-mediated immunity, particularly T cell-mediated
immunity [7]. The selected antigen for this study was the
LALF32-51-E7. The LALF32-51-E7 is a fusion protein
comprising a cell penetrating peptide and HPV-16 E7 mutein
that was designed to be an antigen of a protein-based thera-
peutic vaccine against HPV-16 induced lesions [8]. In this
study we demonstrated that LALF32-51-E7 combined with
aluminum hydroxide adjuvant promotes a Th1 immune
response and consequently an anti-tumor response in the TC-1
tumor model.
2. Materials and methods2.1. Proteins and peptidesThe recombinant HPV-16 E7 protein and LALF32-51-E7
fusion protein were purified as previously described [8,9]. The
endotoxin content in the final protein preparations was less
than 0.05 EU/mg as measured by the chromogenic Limulus
ameobocyte lysate assay (Lonza, USA).
The HPV-16 E749-57 peptide (RAHYNIVTF), a defined H-
2Db-restricted cytotoxic T lymphocyte (CTL) epitope [10]; the
HPV-16 E748-57 peptide (DRAHYNIVTF), a defined CD4 T
cell epitope [11] and the LALF32-51 (HYRIKPTFRRLKW-
KYKGKFW) from the Limulus anti-lipopolysaccharide factor,
were synthesized and purified as previously described [8].2.2. AdjuvantsVery small size proteoliposomes (VSSP) were obtained from
the Center of Molecular Immunology, Havana, Cuba and pro-
duced as described by Estevez et al. [12]. The Al(OH)3 adjuvant
(Alhydrogel) was obtained from Brenntag Biosector, Denmark.2.3. Vaccine formulationsWe used in all experiments 120 mg of LALF32-51-E7 per
mouse either alone, mixed with 200 mg of VSSP (LALF32-51-
E7 þ VSSP) or Al(OH)3-adsorbed [LALF32-51-E7 þ
Al(OH)3]. We used 0.6 mg Al
3þ per dose in all formulations
containing Al(OH)3. The adsorption of LALF32-51-E7 to
Al(OH)3 was estimated to be >95%.2.4. Mice and immunizationsFemale C57BL/6 mice, 6e8 weeks old (CENPALAB,
Cuba) were injected subcutaneously in the right flank
twice or four times at 7-days intervals. The experimental
methods were approved by the Animal Care and Use
Committee of the Center for Genetic Engineering and
Biotechnology and were conducted in accordance with the
Health Guide for the Care and Use of Laboratory Animals
(HGCULA).2.5. Selection of tumourigenic challenge cell line TC-1*
and implantation of tumors in miceTheTC-1 cell linewas kindly provided byDr. T.C.Wu (Johns
Hopkins University, Baltimore) and maintained as described by
Lin et al. [13]. To prepare more tumourigenic TC-1 cells, mice
were challenged subcutaneously with TC-1 cells in the right leg
and when the tumors reached a size of 1.0e1.5 cm they were
excised and further sub-cultured. The released cells were
expanded in medium and then subjected to two subsequent
passages in mice. The resulting cells were named TC-1*.
For the experiments, mice were challenged subcutaneously
in the right leg with 5  104/mouse of TC-1* cells. Starting
5e7 days later and every 2 days thereafter the area was
observed and palpated for the presence of a tumor nodule.
When the presence of tumors was apparent, their diameters
were measured using electronic digital calipers (Kell-Strom,
Canada). Tumor volumes were calculated according to:
(length  width2)/2 [14].2.6. ELISA assayA pool of sera in each group of mice was prepared seven
days after the last immunization. The high-binding plates
(Costar) were coated for 16 h at 4 C with 5 mg/mL of E7
protein or 10 mg/mL of LALF32-51 peptide or were coated for
2 h at 37 C with 5 mg/mL of LALF32-51-E7 protein. Serial
dilutions of mouse sera were added in duplicates. The reaction
was developed for 10 min with 3,30,5,50-Tetramethylbenzidine
substrate solution (Invitrogen, USA) and the absorbance read
at 450 nm in a microplate reader (Sensident scan, Labsystems,
Finland). Sera were designated positive at a given dilution if
the absolute optical density was equal to five standard de-
viations (SD) above the mean optical density of control wells.2.7. Evaluation of IgG subclassesThe plates were coated with 5 mg/mL of E7 protein. The
IgG2c and IgG1 subclasses in sera were determined by ELISA
using the antibodies from SouthernBiotech and following the
manufacturer's instructions.2.8. IFN-g ELISPOTIFN-g ELISPOT assay was performed using a Mouse IFN-
g ELISpotPLUS kit (Mabtech, Sweden). Pooled splenocytes
from immunized mice were prepared seven days after the last
immunization in serum-free culture medium (Cellular Tech-
nology Ltd.). Triplicates cultures (2  105 splenocytes per
well) were incubated in a round-bottom plate with 10 mg/mL
of E749-57 peptide, 10 mg/mL of E748-57 peptide or medium
alone for 48 h at 37 C/5% CO2. Then, all the content of this
plate was transferred to the ELISPOT pre-coated plate and
incubated for 24 h at 37 C/5% CO2. The incubations with the
antibodies and the development of the enzymatic reaction
were done as described by Granadillo et al. [8]. The spots were
counted using AELVIS ELISPOT reader and software.
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was done as previously described [8]. Briefly, pooled spleno-
cytes from mice were obtained seven days after the last im-
munization and were restimulated in the presence of E749-57
peptide to be used as effectors cells. Pooled splenocytes from
naïve mice were pulsed with E749-57 and then labeled with
CFSE to be used as target cells. The effector and target cells
were co-incubated at effector/target ratio of 25:1 and triplicate
samples were acquired in a flow cytometer (Partec, Germany).2.10. IL-12 p40 measurementFig. 1. LALF32-51-E7 þ Al(OH)3 immunization protect mice against TC-1*
tumor challenge. Mice were immunized twice. Fourteen days later, they
were challenged and monitored until tumor was apparent in all animals treatedIL-12 p40 concentration in serum from vaccinated tumor-
bearing mice was determined using Quantikine Murine IL-
12 p40 Immunoassay kit (R&D, USA).with PBS (day 10). Compared with the immunization with LALF32-51-E7 and
PBS, the immunization with LALF32-51-E7 þ Al(OH)3 induced statistically2.11. Cytokines evaluation by RT-PCR
significant protection against tumor challenge. *p < 0.01 LALF32-51-
E7 þ Al(OH)3 vs. LALF32-51-E7; ManneWhitney test.Peripheral blood mononuclear cells (PBMC) from healthy
subjects were prepared by Ficoll density-gradient centrifuga-
tion (Bio-Sciences AB). One million cells were incubated with
medium, LALF32-51 peptide, LALF32-51-E7 protein, LALF32-
51-E7 þ Al(OH)3 and LPS from E. coli strain 0111:B4 for
5 h at 37 C/5% CO2. Total RNA was isolated using TriRe-
agent (Sigma, USA). The expression of Th1/Th2 cytokines
was detected using the multiplex PCR kit (Maxim Biotech,
USA).2.12. Statistical analysisThe statistical significance in tumor volumes was analyzed
using the ManneWhitney U-test. The differences in tumor
protection and survival were evaluated using the log-rank test.
Analyses were performed using GraphPad Prism version 6.0
statistical software (GraphPad Software).
3. Results3.1. LALF32-51-E7 protein combined with Al(OH)3
adjuvant protect mice against tumor challengeTo examine the ability of LALF32-51-E7 þ Al(OH)3 im-
munization to confer protection against challenge with TC-1*
cells, mice (10 per group) were injected twice with LALF32-51-
E7; LALF32-51-E7 þ Al(OH)3 and PBS. Fourteen days later
mice were challenged with TC-1* cells, that in comparison
with parental TC-1 cells had a relatively higher tumour-
igenicity causing a greater and earlier mortality of the mice.
Mice were followed until the tumor incidence in PBS-
treated group was 100%. Fig. 1 shows that tumor challenge
resulted in the appearance of palpable tumors at 10 days post-
implantation in 100% of mice immunized with PBS and in
90% of mice immunized with LALF32-51-E7. Compared with
PBS-treated group, the immunization with LALF32-51-E7 did
not protect mice against challenge with TC-1* cells( p ¼ 0.8460). In contrast, only 40% of mice vaccinated with
LALF32-51-E7 þ Al(OH)3 developed tumors at day 10.
Compared with LALF32-51-E7 and PBS, the immunization
with LALF32-51-E7 þ Al(OH)3 induced statistically significant
protection against tumor challenge ( p ¼ 0.0161 and
p ¼ 0.0084, respectively).3.2. Therapeutic immunization with LALF32-51-E7
protein in combination with Al(OH)3 adjuvant induces a
potent anti-tumor and survival responseSince the data shown in Fig. 1 indicate that animals were
protected with only two immunizations of LALF32-51-
E7 þ Al(OH)3, we investigated the effect of a regimen of four
immunizations in the therapeutic setting of the TC-1 model.
Mice (8 per group) were challenged with TC-1* cells. When
the animals developed palpable tumors (day 12), they were
immunized with LALF32-51-E7 LALF32-51-E7 þ VSSP,
LALF32-51-E7 þ Al(OH)3,VSSP, Al(OH)3 and PBS. The
groups immunized with VSSP, Al(OH)3 and PBS were
considered the control groups. The mice received four im-
munizations. The tumor volumes in each group of mice were
monitored until the first mouse died (day 33). As shown in
Fig. 2A, the immunization with LALF32-51-E7 alone or with
LALF32-51-E7 combined with adjuvants induced response
against the tumor compared with the control immunized
groups ( p < 0.001). The immunization with LALF32-51-
E7 þ Al(OH)3 induced a suppression of tumor growth com-
parable to that induced by LALF32-51-E7 þ VSSP ( p ¼ 1) and
both preparations generated a better anti-tumor response
compared with the immunization with LALF32-51-E7
( p ¼ 0.0356 and p ¼ 0.0379, respectively).
To determine the effects of therapies on long-term survival,
these animals were followed until the last mouse of control
groups died (day 53). Fig. 2B shows that 100% of PBS, VSSP
Fig. 2. The therapy with LALF32-51-E7 þ Al(OH)3 induces a potent anti-tumor response in the TC-1 model. (A) Mice were challenged and when developed
palpable tumors they were immunized. They received four immunizations and tumor volumes were assessed 33 days post-implantation. The immunization with
LALF32-51-E7 þ Al(OH)3 induced a response comparable to that induced by LALF32-51-E7 þ VSSP ( p ¼ 1) and generated a better anti-tumor response compared
with the immunization with LALF32-51-E7 (*p ¼ 0.0356 and *p ¼ 0.0379, respectively). Data are represented as individual tumor volumes and means in each
group. (B) Mice were monitored for survival until day 53. The survival in the LALF32-51-E7 þ VSSP, LALF32-51-E7 þ Al(OH)3 and LALF32-51-E7 treated-groups
was statistically significant relative to controls (***p < 0.001).
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53 days. In contrast, survival over this period in the LALF32-
51-E7 þ VSSP, LALF32-51-E7 þ Al(OH)3 and LALF32-51-E7
treated-groups was 100%, 87.5% and 62.5%, respectively, and
were statistically significant relative to control groups
( p < 0.001).3.3. The combination of LALF32-51-E7 with Al(OH)3
adjuvant induce an E7-specific IgG antibody response
with a subclass pattern predominantly Th1Mice (4 per group) were immunized with LALF32-51-E7,
LALF32-51-E7 þ Al(OH)3, LALF32-51-E7 þ VSSP, Al(OH)3,
VSSP and PBS. The mice received four immunizations. A
pool of sera in each group was prepared 7 days after the last
immunization and the antibody responses against LALF32-51
peptide, E7 protein and LALF32-51-E7 protein was evaluated
by ELISA (Fig. 3A). As expected, the groups of mice
immunized with the LALF32-51-E7 protein alone or com-
bined with Al(OH)3 or VSSP adjuvants elicited a specific
IgG antibody response against the E7 protein (titers of
1:42 355, 1:37 306 and 1:95 671, respectively) and against
LALF32-51-E7 protein (titers of 1:119 124, 1:71 399 and
1:149 499, respectively). The immunization with LALF32-51-
E7 þ Al(OH)3 did not elicit antibody response to the
LALF32-51 peptide while the immunization with LALF32-51-
E7 alone and LALF32-51-E7 þ VSSP elicited a low antibody
titers (1:915 and 1:1314, respectively). Therefore, the IgG
titers detected against LALF32-51-E7 fusion protein were
predominantly directed against E7 protein and not against
the LALF32-51 peptide. In general, the group immunized with
LALF32-51-E7 þ Al(OH)3 reached the lowest titers and the
group immunized with LALF32-51-E7 þ VSSP reached the
highest.We also evaluated the IgG2c and IgG1 subclasses to
explore their contribution in the total IgG response detected
against E7 protein. In C57BL/6 mice a high IgG2c:IgG1 ratio
is associated with Th1 responses and a lower ratio with Th2
responses. As shown in Fig. 3B, the immunization with
LALF32-51-E7 alone or with LALF32-51-E7 combined with
adjuvants induced an IgG subclass pattern predominantly
IgG2c.3.4. The immunization with LALF32-51-E7 combined with
Al(OH)3 adjuvant induces an E7-specific CD8
þ T-cell
responseTo determine the E7-specific IFN-g-secreting CD8þ T cell
precursor frequencies and the cytolytic activity generated by
the immunization, ELISPOT and cytotoxicity assays were
performed. Mice (4 per group) were immunized four times
with LALF32-51-E7, LALF32-51-E7 þ Al(OH)3, LALF32-51-
E7 þ VSSP, Al(OH)3, VSSP, and PBS. Seven days after the
last immunization a single-cell suspension of pooled spleens
in each group were prepared and stimulated with peptides and
medium. As shown in Fig. 3C, the immunization with
LALF32-51-E7 þ Al(OH)3 can promote the generation of IFN-
g producing HPV-16 E7-specific T cell precursors in vivo. The
number of IFN- g producing cells obtained in response to the
stimulation with E749-57 peptide was similar in the groups
immunized with LALF32-51-E7 þ Al(OH)3 and LALF32-51-
E7 þ VSSP. Also, the number of IFN- g producing cells
generated in the above mentioned groups was higher than in
the mice immunized with the LALF32-51-E7. However, the
response to the stimulation with E748-57 T helper peptide in the
group vaccinated with LALF32-51-E7 þ VSSP was higher than
in the groups immunized with LALF32-51-E7 and LALF32-51-
E7 þ Al(OH)3.
Fig. 3. The immunization with LALF32-51-E7 þ Al(OH)3 induces IgG antibody responses with a subclass pattern predominantly Th1 and induces a CD8þ T-cell
response. Mice received four immunizations and seven days after the last immunization a pool of sera and a pool of splenocytes were prepared in each group. (A)
The antibody responses were evaluated by ELISA. The titers detected against LALF32-51-E7 fusion protein were predominantly against E7 protein and not against
the LALF32-51 peptide. Bars represent mean ± S.D. (B) E7-specific IgG2c and IgG1 antibody responses were determined by ELISA. The immunization with
LALF32-51-E7 þ Al(OH)3 induced a subclass pattern predominantly IgG2c. (C) The splenocytes were restimulated and the number of IFN-g producing cells was
assessed by ELISPOT. The response to the stimulation with E749-57 peptide was similar in the groups of mice immunized with LALF32-51-E7 þ Al(OH)3 and
LALF32-51-E7 þ VSSP and better than in the mice immunized with LALF32-51-E7. Data are expressed as mean number of spot forming cells (SFC) per 106
splenocytes ± S.D. (D) The cytotoxic capacity of the splenocytes was also assayed. The results were consistent with the data from ELISPOT. Data are expressed as
means of percentage of cytotoxicity ± S.D.
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were consistent with the data from ELISPOT. The HPV-16 E7-
specific lysis of CTL from mice vaccinated with LALF32-51-
E7 þ Al(OH)3 was very closed to those obtained from mice
vaccinated with LALF32-51-E7 þ VSSP and higher than ob-
tained from mice immunized with LALF32-51-E7.3.5. The immunization with LALF32-51-E7 enhance the
levels of IL-12Taking into account our results indicating that the use of
Al(OH)3 adjuvant can promote a Th1 immune response and
based on previous results describing their inefficiency as
activator of Th1 responses by inhibiting the secretion of
bioactive IL-12 by dendritic cells [4], we investigated if the
therapy with our antigen LALF32-51-E7 in the TC-1 tumor
model promotes the secretion of IL-12 and if Al(OH)3 adju-
vant could suppress this effect. Mice (6 per group) were
challenged and when developed palpable tumors, they were
immunized twice with LALF32-51-E7, LALF32-51-
E7 þ Al(OH)3 and PBS. A group of naïve mice was used as
control. At 24 days post-tumor implantation, when the group
of mice vaccinated with LALF32-51-E7 and LALF32-51-
E7 þ Al(OH)3 showed an anti-tumor response statistically
significant relative to the PBS-treated group (mean of tumor
volumes per group of 86 mm3, 56 mm3 and 342 mm3,
respectively), the blood of each mouse was collected and the
concentration of IL-12 p40 in serum was analyzed. As shown
in Fig. 4A and compared with the levels of IL-12 detected in
the group of placebo mice (150 pg/mL), the vaccination of
tumor-bearing mice with LALF32-51-E7 protein and LALF32-
51-E7 þ Al(OH)3 enhanced the secretion of IL-12 (286 pg/mL
and 325 pg/mL, respectively). These values were “very
closed” to the levels detected in the non-immunized and non-Fig. 4. The immunization with LALF32-51-E7 enhances the levels of IL-12 due to the
and when developed palpable tumors they were immunized twice. The concentratio
vaccination of tumor-bearing mice with LALF32-51-E7 and LALF32-51-E7 þ Al(OH
were incubated with various stimuli for 5 h. DNA molecular weight marker (Lane 1)
peptide (Lane 3), cells incubated with LALF32-51-E7 (Lane 4), cells incubated with
RNA was isolated and the expression of cytokines was assessed by RT-PCR. As stumor bearing mice (331 pg/mL) suggesting a positive effect
of the vaccination on the immune system to control the tumor.
Our results suggest a dominance of the IL-12 stimulation over
the IL-12 inhibition after the immunization with LALF32-51-
E7 þ Al(OH)3.3.6. LALF32-51 peptide induce the expression of IL-12
and IFN-gIn our previous studies we demonstrated that a cyclic
peptide corresponding to residues 31 to 52 of LALF is able to
modulate the immune response and to induce the release of
IFNs (IFN-g and -a) in PBMC stimulated with the peptide
[15]. In this study we investigated the role of LALF32-51
peptide as an immunomodulator based on the results that
suggest the immunization with LALF32-51-E7 and LALF32-51-
E7 þ Al(OH)3 promote the secretion of IL-12. The expression
of Th1/Th2 human cytokines in PBMC stimulated with
LALF32-51 peptide, LALF32-51-E7 protein and LALF32-51-
E7 þ Al(OH)3 was assessed by RT-PCR. As shown in Fig. 4B,
the LALF32-51 peptide induced the expression of the Th1 cy-
tokines IL-12 and IFN-g and not induced the expression of the
Th2 cytokines IL-4, IL-5, IL-10, and IL-13. The same cyto-
kine profile was obtained when the PBMC were incubated
with LALF32-51-E7 and LALF32-51-E7 þ Al(OH)3. These re-
sults demonstrate that LALF32-51 peptide have immunosti-
mulatory properties and corroborate that Al(OH)3 adjuvant
doesn't suppress the expression of IL-12 induced by LALF32-
51-E7 protein. Also, these results suggest that the induction of
the expression of IL-12 mediated by LALF32-51 peptide in
PBMC could be one of the reasons why alum promotes a
cell-mediated immune response when is combining with
LALF32-51-E7 antigen.immunostimulatory capacity of LALF32-51 peptide. (A) Mice were challenged
n of IL-12 p40 in serum was analyzed at 24 days post-tumor implantation. The
)3 enhanced the secretion of IL-12. Bars represent means ± S.D. (B) PBMC
, cells incubated with culture medium (Lane 2), cells incubated with LALF32-51
LALF32-51-E7 þ Al(OH)3 (Lane 5) and cells incubated with LPS (Lane 6). The
hown, the LALF32-51 peptide induced the expression of IL-12 and IFN-g.
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Although the last two decades of systematic research into
the nature of alum-based adjuvants has contributed signifi-
cantly to understand their nature and limitations as the stim-
ulators, the more detailed mode of action of these adjuvants is
still not completely understood. Therefore, the question about
the ability of alum to promote a specific type of response
depending on the nature of the antigen is still open.
Taking into account the findings mentioned previously, we
investigated if the therapeutic vaccination with our antigen
LALF32-51-E7 combined with Al(OH)3 adjuvant could
generate a cell-mediated immune response.
In a previous study in the TC-1 model we demonstrated that
the immunization with LALF32-51-E7 fusion protein without
adjuvant induces a potent anti-tumor response and their
combination with VSSP adjuvant promotes a benefit in the
survival of the immunized animals [8]. In this study, we used
VSSP as our model of Th1 polarizing adjuvant and we
developed TC-1* cells more tumourigenic as compared to the
original cell line to test the capacity of Al(OH)3 as adjuvant.
We have found that the use of Al(OH)3 in combination with
our vaccine antigen induced a predominantly Th1 immune
response as well as VSSP.
We also demonstrated by ELISA, ELISPOTand CTL assays
the capacity of alum to induce a Th1 immune response. The
evaluation of the antibodies response against LALF32-51 pep-
tide, E7 protein and LALF32-51-E7 fusion protein in immunized
mice suggest that the antibodies response generated by the im-
munization is specific and preferentially against E7 protein. In
the evaluation of IgG2c and IgG1 subclasses we detected levels
of IgG2c higher than IgG1 in the serum ofmice immunized with
the protein alone and combinedwith alumorVSSP, suggesting a
preferentially Th1 immune response.
In our experiments to measure the cellular immune response,
that is responsible for the anti-tumor effect, we detected an E7-
specific IFN-g-secreting CD8þ T cell response in the groups of
mice immunized with LALF32-51-E7 þ Al(OH)3 and LALF32-
51-E7 þ VSSP. This response to the CTL epitope E749-57 was
similar in both groups and was greater with respect to the group
immunized with the protein without adjuvant. However, the
IFN-g response to the stimulation with the T helper peptide
E748-57 was higher in the group immunized with LALF32-51-
E7 þ VSSP suggesting a possible role of VSSP in activate the
CTL response with the contribution of the T helper lympho-
cytes. The results obtained in the CTL assay shows the similar
cytotoxic capacity of the effector cells derived from mice
immunized with the protein combined with alum or VSSP ad-
juvants. Taken together the results obtained indicates that the
use of alum as adjuvant combined with the fusion protein
LALF32-51-E7 promote a cell-mediated immunity similar to that
obtained with the combination of our antigen with a Th1 adju-
vant model (VSSP).
The differentiation of Th1 cells requires IL-12, which
promotes IFN-g secretion by T cells and NK cells [16] and is
produced by dendritic cells in response to stimulation with
pathogen-associated molecular patterns. Taking into account:(a) the report suggesting the inefficiency of alum as activators
of Th1 responses is a consequence of its inhibitory effects on
IL-12 production [4]; (b) other reports describing that
combining alum with IL-12 enhance the Th1 responses to an
antigen [5,6]; (c) the properties of LALF32-51 as cell pene-
trating and immunomodulatory peptide [8] and (d) the
particulate-aggregate nature of the LALF32-51-E7 protein ob-
tained in E. coli [9], we investigated if our promising results
with LALF32-51-E7 þ Al(OH)3 could be related with the
secretion of IL-12 induced by LALF32-51 peptide. In this study
we demonstrated that the immunization with LALF32-51-E7
alone and with LALF32-51-E7 þ Al(OH)3 promotes the
secretion of IL-12 p40 in tumor-bearing mice that could be
associated with the immune-modulator properties of LALF32-
51 peptide that induced the expression of IL-12 p40 and IFN-g.
Also, the Al(OH)3 adjuvant didn't suppress the expression of
IL-12 induced by LALF32-51-E7 protein.
The LALF32-51 peptide is a key component of the LALF32-
51-E7 fusion protein, overcoming the poor immunogenicity of
the E7 protein through their cell-penetrating capacity [8] and
their immunomodulatory properties based on the induction of
the Th1 cytokines IL-12 and IFN-g. That's why the immuni-
zation with the LALF32-51-E7 fusion protein without adjuvant
generates a potent CD8þ T cell and anti-tumor responses in
mice and is one of the reasons why alum improve a cell-
mediated immune response when is combined with LALF32-
51-E7. The experiences obtained in humans with other protein-
based therapeutic HPV vaccines has demonstrated the
importance of including an adjuvant in the vaccine preparation
to improve the immune response necessary in the treatment of
immunocompromised individuals. Despite of the well known
capacity of alum adjuvant to induce a humoral immune
response [2,3] instead of the well known capacity of VSSP
adjuvant as a powerful inducer of the activation of cytotoxic T
lymphocytes to proteins [17], we demonstrated in this study
that alum can also promote the activation of the cell-mediated
immunity when is combined with our antigen.
In conclusion, through a series of experiments we showed
that our antigen LALF32-51-E7 combined with alum adjuvant
promotes a Th1 immune response and consequently an anti-
tumor response in the TC-1 tumor model. Based on our re-
sults, we suggest not to underestimate the capacity of Al(OH)3
as adjuvant for vaccines that require of the induction of the
cellular immunity.
The results obtained by us demonstrating the anti-tumor
response induced by therapeutic vaccination with LALF32-51-
E7 þ Al(OH)3 could have an important application in future
clinical trials in women with cervical intraepithelial neoplasia
grade 1 (CIN 1). CIN 1 is most frequently in young women in
reproductive age; therefore, the availability of a therapeutic
vaccine containing a safe adjuvant as alum could be of great
importance.
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